Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
25 Apr 2019  |  North America
Increased Investment in Adult Immunization and Improved Mammalian Cell-culture Expression Systems will Drive Growth and Profitability
The report provides an overview of the global vaccine market estimating the market size broken down by different segments. Vaccines, though a sub-set of biologics, have a completely different dynamic. Not only are they largely designed for a healthy cohort but are also exponentially influenced by government actions and policies. While old generatio...
11 Apr 2019  |  North America
Collision of Healthcare with Life Sciences IT Systems will Continue to Transform the Clinical Trials Market
Despite the term patient centricity gaining currency in the industry, there is a degree of variability in a companies’ approach and strategic priorities. Frost & Sullivan sees digitization playing a critical role in transforming the clinical trial model from traditional, high-cost, and difficult-to-access centralized settings to more patient-cent...
10 Apr 2019  |  Africa
Greater Regulatory Control and a Shift of Focus Away from Costly and Branded Drugs will Increase Generic Drugs’ Market Share
The African continent grapples with a huge burden of communicable diseases, particularly HIV/AIDS, tuberculosis, and malaria. With African governments facing major health financing challenges, a significant proportion of these disease areas are financed by global aid organizations that are also helping in poverty eradication in the continent. Paral...
04 Apr 2019  |  Asia Pacific
Investment in Private and Specialty Care Clinics Drives Growth
China is one of the fastest growing healthcare markets in the world. Traditionally, healthcare services have been dominated by the public sector; however, 2014 onward, the trend reversed with greater private sector participation. China still faces a number of challenges: unequal distribution of healthcare resources across the country; lack of an ef...
01 Apr 2019  |  Asia Pacific
Increase in Universal Health Support for Private Healthcare will Boost Test Volumes in Both Public and Private Sectors
Clinical laboratories are an essential part of the health industry. Approximately 80% of physicians' diagnoses is estimated to be the result of laboratory tests. The constant pressure to reduce healthcare spending is shifting healthcare application in favor of the laboratory, making it a more valuable part of the treatment plan. Vietnam CLT marke...
30 Mar 2019  |  Global
Synthetic Biology as a Profound Transformative Technology
Synthetic biology is being supported by a convergence of vanguard technologies. In the era of precision medicine and smart cities, synthetic biology plays a crucial role across multiple sectors and industries. Breakthrough technologies are facilitating the successful implementation of synthetic biology approaches, and also helping in addressing the...
30 Mar 2019  |  North America
Multiple Investigational New Drugs with high potential for better treatment outcomes progressing through critical stages of clinical development
Non-Alcoholic Steatohepatitis or NASH is a liver disorder that is characterized by the build-up of fat in liver in addition to inflammation and liver cell damage eventually progressing to cirrhosis. Currently lifestyle interventions are suggested for the treatment of NASH with no drugs having been approved for the condition. Multiple drugs are at ...
28 Mar 2019  |  Asia Pacific
Rising Demand for Diagnostics Services from the Ageing Population and Growing Prevalence of Chronic Diseases to Drive Market Growth
This study focuses on clinical lab services in Thailand. A detailed analysis is provided on clinical testing services at public hospital labs and private hospital labs. Specialised labs are integrated into the independent reference labs segment. Certain trends with regard to physician office labs (POLs) in retail clinics have been mentioned in the ...
28 Mar 2019  |  Asia Pacific
Shift toward Preventive Healthcare is Driving Market Growth
The market for healthcare services in Malaysia is less developed, with many clinical testing services being unavailable outside of cities. Unsubstantiated disease and unconfirmed mortality diagnoses are common in the country despite universal care, significant mixed investment in the local healthcare system, and health expenditure favourable to oth...
20 Mar 2019  |  North America
As Novel Technologies Find Traction, Industry Focus Will Shift Towards Successful Monetization to Deliver Value-based Care
he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...